American Conference on Pharmacometrics (ACoP) 2025, Colorado

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, recently attended the American Conference on Pharmacometrics (ACoP) 2025 (18-21 October) – one of the key gatherings for those shaping the future of quantitative drug development – for the first time in a number of years.  

 

Dr Mark Davies, Head of Quantitative Pharmacology and Data Science at Physiomics, joined fellow experts in Colorado to explore the latest advances in QSP, PK/PD, pharmacometrics, and MIDD to discuss how these data-driven techniques can be applied to refine decision-making, optimise trials, and accelerate progress from lab to clinic. 

 

For more information about Physiomics’ services and partnerships visit www.physiomics.co.uk.  

   

 

Enquiries: 

Physiomics plc 

Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980 

  

Hybridan LLP (Broker) 

Claire Louise Noyce 

+44 (0) 203 764 2341 

  

Strand Hanson Ltd (NOMAD) 

James Dance & James Bellman 

+44 (0)20 7409 3494 

   

  

Notes to Editor 

   

About Physiomics 

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.